Future work should also explore the feasibility of translating the CASP9-based prognostic model into clinically applicable tools, such as qPCR panels or IHC-based assays, to improve risk stratification and personalized treatment strategies in ccRCC. The gene discussed is CASP9; the disease is nonpapillary renal cell carcinoma.